CURRICULUM VITAE

STEVEN EDWARD COUTRÉ
Division of Hematology
Stanford University School of Medicine
875 Blake Wilbur Drive
Stanford, CA 94305

Personal Data:

Date of Birth:	May 27, 1959
Birthplace:	Evanston, Illinois
Marital Status:	Married, two children

Education:

1977-81	Northwestern University, Evanston, IL, B.A., 1981
1981-86	Stanford University School of Medicine, Stanford, CA, M.D., 1986

Post-Graduate Training:

1986-87	Assistant Resident in Medicine, Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT
1987-89	Resident in Medicine, Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT
1989-92	Postdoctoral Fellow, Division of Hematology, Stanford University School of Medicine, Stanford, CA
1990-92	Postdoctoral Fellow, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Professional Positions:

1992-94	Research Scientist, Preclinical Development, Vascular Biology and Medicine, Gilead Sciences, Foster City, CA
1994-95	Physician in private practice, Deerpath Medical Associates, Lake Forest Hospital, Lake Bluff, IL

Academic Positions:

1995-96	Acting Assistant Professor of Medicine (Hematology), Stanford University School of Medicine, Stanford, CA
1996-2004	Assistant Professor of Medicine (Hematology), Stanford University School of Medicine, Stanford, CA
2004-present	Associate Professor of Medicine (Hematology), Stanford University School of Medicine, Stanford, CA

Certification:

1988	Diplomate, National Board of Medical Examiners
1993	Diplomate, American Board of Internal Medicine
1994	Diplomate, American Board of Medical Specialties (Hematology)
1988-89	Medical License, State of Connecticut
1994-97	Medical License, State of Illinois
1989-present	Medical License, State of California

Academic Honors, Awards, Professional Organizations:

1981	Honors in Biochemistry and Molecular Biology, Northwestern University
1983	Stanford Alumni Medical Student Scholarship, Stanford University School of Medicine
1986	Research Honors Award, Stanford University School of Medicine
1990	Timothy F. Beckett, Jr. Award for Excellence in Clinical Teaching, Stanford University School of Medicine
1991	Bernard Cohen Postdoctoral Fellowship, Stanford University School of Medicine
1991-92	Physician Scientist Award (K11AIO1056-01), National Institutes of Health
2002	Division Teaching Award, Stanford University School of Medicine
1994-present	American Society of Hematology
1996-present	Southwest Oncology Group, Leukemia Committee
1998-present	National Comprehensive Cancer Network, Acute Myelogenous Leukemia Panel

Local Participation:

1996-97	Member, Operations Improvement Committee, Stanford University Hospital
1996-97	Member, Practice Operations Committee, Stanford University Hospital
1996-98	Physician Leader, Physician Order Entry, Stanford University Hospital
1996-99	Member, Physician Computer Advisory Team, Stanford University Hospital
1997-99	Member, Medical Board, Stanford University Hospital
1997-01	Member, Quality Assurance Committee, Department of Medicine
1998-99	Member, Clinician Advisory Group, Stanford University Hospital
1999-00	Member, Faculty Senate, Stanford University School of Medicine
1996-05	Member, Committee on Residency Training and Clinical Service, Department of Medicine
2005-06	Medical Director, MedVIII Hematology Inpatient Service, Stanford University Hospital
2000-present	Member, Department of Medicine Leadership Group, Department of Medicine
2000-present	Medical Director, Hematology Outpatient Clinic, Stanford University Hospital
2005-present	Member Cancer Center Operations Committee, Stanford Cancer Center
2005-present	Member, Clinic Chiefs Committee, Stanford University Hospital
2005-present	Disease Management Program Leader, Stanford Cancer Center
2008-present	Data Safety Monitoring Committee, Cancer Clinical Trials Office
2009-present	Member, Quality Council, Department of Medicine
2009-present	Associate Program Director, Internal Medicine Residency Program, Department of Medicine
2009-present	Medical Service Director, Stanford University Hospital
2009-present	Compensation Committee, Department of Medicine
2010-present	Disease Management Group Leader, Stanford Cancer Center

Clinical Trial Principal Investigator:

Ongoing Research Support

08/13/07-08/12/10

Study: A Phase I, Multicenter, Dose-escalation Study of CAT-8015 in Patients with Relapsed or Refractory Hairy Cell Leukemia.
Role: Co-Investigator for the overall study
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Medimmune
Planned Number of Subjects: Overall 40, Stanford 3 (actual 2)
Registration Number at ClinicalTrials.gov: NCT00586924

06/17/08-06/16/10

Study: A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in first Relapse.
Role: Co-Investigator for the overall study
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Cyclacel Ltd.
Planned Number of Subjects: Overall 140, Stanford 10 (actual 9)
Registration Number at ClinicalTrials.gov: NCT00590187

07/20/04-12/31/10

Study: A Multi-Center Phase II Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath® (FCCam) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia.
Role: Principal investigator for the overall study
Type of Study: Investigator-initiated multi-institution trial
Sponsor: Berlex (Bayer)
Planned Number of Subjects: Overall 25, Stanford 15 (actual 17)
Registration Number at ClinicalTrials.gov: NCT00230282

02/12/08-12/31/10

Study: A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy With ATRA and Arsenic Trioxide (STAR-1).
Role: Co-Investigator for the overall study
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Innovive
Planned Number of Subjects: Overall 50, Stanford 3 (actual 2)
Registration Number at ClinicalTrials.gov: NCT00520208

02/11/08-6/30/10

Study: Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects who are Experiencing Clinical Benefit on Current START Protocols: Long Term Safety and Efficacy.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Bristol Myers Squibb
Planned Number of Subjects: Overall NA, Stanford 2 (actual 2)
Registration Number at ClinicalTrials.gov:

09/17/07-09/13/10

Study: A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marquibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second or Greater Relapse.
Role: Co-Investigator for the overall study
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Hana Biosciences
Planned Number of Subjects: Overall 56, Stanford 5 (actual 2)
Registration Number at ClinicalTrials.gov: NCT00495079

11/01/08-10/31/16

Study: A Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Wyeth Pharmaceuticals
Planned Number of Subjects: Overall 412, Stanford 5 (actual 1)
Registration Number at ClinicalTrials.gov: NCT00574873

08/01/06-07/31/12

Study: SWOG S0521, A Randomized Trial of Maintenance Versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III.
Role: Principal investigator for the overall study (National PI for the Intergroup)
Type of Study: Cooperative group clinical trial
Sponsor: SWOG-CTEP
Planned Number of Subjects: Overall 500, Stanford 15 (actual 8)
Registration Number at ClinicalTrials.gov: NCT00492856

08/01/06-07/31/12

Study: SWOG S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Cooperative group clinical trial
Sponsor: SWOG-CTEP
Planned Number of Subjects: Overall 70, Stanford 3 (actual 1)
Registration Number at ClinicalTrials.gov: NCT00551460

08/01/06-07/31/12

Study: SWOG S0106, A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) during Induction Therapy versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg®) or no Additional Therapy for Patients Under Age 56 with Previously Untreated de Novo Acute Myeloid Leukemia (AML).
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Cooperative group clinical trial
Sponsor: SWOG-CTEP
Planned Number of Subjects: Overall 684, Stanford 20 (actual 24)
Registration Number at ClinicalTrials.gov: NCT00085709

02/17/09-02/16/11

Study: A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients with Select, Relapsed or Refractory Hematologic Malignancies.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Calistoga, Inc.
Planned Number of Subjects: Overall 72, Stanford 8 (actual 15)
Registration Number at ClinicalTrials.gov: NCT00710528

11/05/08-011/30/17

Study: A Phase III, Randomized, Open-label, 3-Arm Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) Plus Low-dose Dexamethasone when given until progressive disease or for 18 Four-week Cycles Versus The Combination of Melphalan, Prednisone, and Thalidomide Given For 12 Six-week Cycles in Patients with Previously Untreated Multiple Myeloma Who Are either 65 Years Of Age Or Older Or Not Candidates For Stem Cell Transplantation.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Celgene, Inc.
Planned Number of Subjects: Overall 1600, Stanford 15 (actual 0)
Registration Number at ClinicalTrials.gov: NCT00689936

05/11/09-04/30/15

Study: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) As Maintenance Therapy For Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy Protocol CC-5013-CLL-002.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Celgene, Inc.
Planned Number of Subjects: Overall 680, Stanford 15 (actual 1)
Registration Number at ClinicalTrials.gov: NCT00774345

08/01/06-07/31/12

Study: S0703, "A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia".
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Cooperative group clinical trial
Sponsor: SWOG-CTEP
Planned Number of Subjects: Overall 139, Stanford 10 (actual 5)
Registration Number at ClinicalTrials.gov: NCT00658814

Completed Research Support

04/22/03-12/31/08

Study: A Multi-Center, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Celgene, Inc.
Planned Number of Subjects: Overall 302, Stanford 10 (actual 4)
Registration Number at ClinicalTrials.gov: NCT00056160

09/29/06-12/30/08

Study: A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Novartis Pharmaceuticals
Planned Number of Subjects: Overall 124, Stanford 3 (actual 0)
Registration Number at ClinicalTrials.gov: NCT00445068

12/09/05-12/08/08

Study: A Phase 1 Trial of AVN-944 in Patients with Advanced Hematologic Malignancies.
Role: Co-Investigator for the overall study
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Avalon Pharmaceuticals
Planned Number of Subjects: Overall 72, Stanford 18 (actual 15)
Registration Number at ClinicalTrials.gov: NCT00273936

03/04/05-08/31/08

Study: A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate.
Role: Co-Investigator for the overall study
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Bristol-Myers Squibb
Planned Number of Subjects: Overall 60, Stanford actual 3
Registration Number at ClinicalTrials.gov: NCT00101595

03/04/05-08/31/08

Study: A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate.
Role: Co-Investigator
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Bristol-Myers Squibb
Planned Number of Subjects: Overall 60, Stanford actual 3
Registration Number at ClinicalTrials.gov: NCT00101816

03/04/05-08/31/08

Study: A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Bristol-Myers Squibb
Planned Number of Subjects: Overall 60, Stanford actual 3
Registration Number at ClinicalTrials.gov: NCT00101647

03/04/05-08/31/08

Study: A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosone-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Imatinib Mesylate (Gleevec™) or Who are Intolerant of Imatinib.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Bristol-Myers Squibb
Planned Number of Subjects: Overall 413, Stanford 8 (actual 6)
Registration Number at ClinicalTrials.gov: NCT00101660

08/14/07-08/13/08

Study: A Phase I/II Dose Escalation Study of MK-0457 in Patients With Leukemia.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Merck Pharmaceuticals
Planned Number of Subjects: Overall 28, Stanford actual 2
Registration Number at ClinicalTrials.gov: NCT00111683

08/14/07-08/31/08

Study: A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Merck Pharmaceuticals
Planned Number of Subjects: Overall 28, Stanford actual 1
Registration Number at ClinicalTrials.gov: NCT00405054

11/15/05-11/14/07

Study: A Multi-Center, Single-arm, Open-label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects with Multiple Myeloma.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Celgene, Inc.
Planned Number of Subjects: Overall 2,000, Stanford actual 31
Registration Number at ClinicalTrials.gov: NCT00179647

08/22/05-08/21/07/07

Study: *SHEPHERD:* Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multi-center Open-label Research Design Study.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Alexion Pharmaceuticals
Planned Number of Subjects: Overall 85, Stanford 3 (actual 2)
Registration Number at ClinicalTrials.gov: NCT00122304

06/01/01-12/31/06

Study: Phase III Multi-Center Trial: ALL-4 MSK: A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone (ALL-2) to a Standard Vincristine/Prednisone Based Regimen (L-20) as Induction Therapy for Adult Patients with Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol.
Role: Co-Investigator for the overall study
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Memorial Sloan Kettering Cancer Center
Planned Number of Subjects: Overall 154, Stanford 3 (actual 7)
Registration Number at ClinicalTrials.gov: NCT00002766

10/01/04-09/30/06

Study: *TRIUMPH:* A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-center, Double blind, Placebo controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Alexion Pharmaceuticals
Planned Number of Subjects: Overall 75, Stanford 3 (actual 2)
Registration Number at ClinicalTrials.gov: NCT00112983

05/01/03-05/31/05

Study: Phase II Study of GLEEVEC™ (Imatinib Mesylate) in Patients with Idiopathic Hypereosinophilic Syndrome (HES).
Role: Principal investigator for the overall study
Type of Study: Investigator-initiated single-institution trial
Sponsor: Novartis, Inc.
Planned Number of Subjets: Overall 25, Stanford actual 5
Registration Number at ClinicalTrials.gov: NCT00230334

05/15/06-02/01/09

Study: A Phase I Study of mAb 216 with Chemotherapy for the Treatment of Adult Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.
Role: Principal investigator
Type of Study: Investigator-initiated single-institution trial
Sponsor: NIH
Planned Number of Subjects: Stanford 15 (actual 9)
Registration Number at ClinicalTrials.gov: NCT00313079

10/31/07-01/27/09

Study: Phase 1 Multi-Center, Dose-Escalation Clinical Study of the Safety and Tolerability of Intravenously Administered SNS-032 Injection, A Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients with Advanced B-Lymphoid Malignancies.
Role: Co-Investigator for the overall study
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Sunesis Pharmaceuticals
Planned Number of Subjects: Overall 34, Stanford 10 (actual 3)
Registration Number at ClinicalTrials.gov: NCT00446342

02/02/04-12/31/09

Study: A Randomized, Open-label Study of Oral CEP-701 Administered in Sequence with Standard Chemotherapy to Patients with Relapsed AML Expressing FLT-3 Mutations.
Role: Co-Investigator for the overall study
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Cephalon, Inc.
Planned Number of Subjects: Overall 220, Stanford 10 (actual 11)
Registration Number at ClinicalTrials.gov: NCT00079482
10/31/07-10/31/09

07/03/08-07/02/10

Study: A Phase I/II Multi-Center, Open Label Study of the Safety and Efficacy of a Stepwise Dose-Escalation Schedule of Lenalidomide Monotherapy in Subjects with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia.
Role: Co-Investigator for the overall study
Type of Study: Industry-initiated multi-institutional trial
Sponsor: Celgene, Inc.
Planned Number of Subjects: Overall 50, Stanford 3 (actual 5)
Registration Number at ClinicalTrials.gov: NCT00419250

08/01/06-07/31/12

Study: Phase III Randomized Multi-Center Trial: SWOG C9710: Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy with or without Arsenic Trioxide as Initial Consolidation Therapy Followed by Maintenance Therapy with Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients with Untreated Acute Promyelocytic Leukemia.
Role: Co-Investigator for the overall study (SWOG national PI)
Sponsor: SWOG-CTEP
Planned Number of Subjects: Overall 522, Stanford actual 4
Registration Number at ClinicalTrials.gov: NCT00003934

08/01/06-07/31/12

Study: SWOG S0530, A Phase II Trial of Cytarabine and Clofarabine in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL).
Role: Principal investigator for a multi-site trial at the Stanford site
Type of Study: Cooperative group clinical trial
Sponsor: SWOG-CTEP
Planned Number of Subjects: Overall 35, Stanford actual 5
Registration Number at ClinicalTrials.gov: NCT00337168

08/01/06-07/31/12

Study: Phase II Multi-Center Trial: SWOG 0010 A Phase II Trial of 506U78 in Patients with Relapsed or Refractory Non-T-Lineage Acute Lymphoblastic Leukemia (ALL).
Role: Principal investigator for the overall study (SWOG national PI)
Type of Study: Cooperative group clinical trial
Sponsor: SWOG-CTEP
Planned Number of Subjects: Overall 20, Stanford actual 3
Registration Number at ClinicalTrials.gov: NCT00006020

BIBLIOGRAPHY

Peer-Reviewed Articles

1. **Coutré SE**, Stanford JM, Hovis JG, Stevens PW, Wu TT; Possible three-dimensional backbone folding around antibody combining site of immunoglobulin MOPC 167; *J Theor Biol*; 92:417-34, 1981.
2. Lifson J, **Coutré S**, Huang E, Engleman EG; Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus induced cell fusion; *J Exp Med*; 164:2101-6, 1986.
3. Khan MM, Fishwild DM, Melmon KL, **Coutré S**, Engleman EG, Bauer JA; A subset of human rosetted lymphocytes contains previously unidentified histamine; *Clin Immunol and Immunopath*; 52:147-59, 1989.
4. Kusumi K, Conway B, Cunningham S, Berson A, Evans C, Iversen AKN, Colvin D, Gallo MV, **Coutré S**, et al; Human immunodeficiency virus type 1 envelope gene structure and diversity *in vivo* and after co-cultivation *in vitro*; *J Virol*, 66:875-85, 1992.

5. DeAnda A, **Coutré S**, Moon M, Vial C, Griffin L, Law V, Komeda M, Leung LLK, Miller DC; Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass; *Ann Thorac Surg*; 58:344-50, 1994.
6. Gibbs CS, **Coutré S**, Tsiang M, Li W-X, Jain AK, Dunn KE, Law VS, Mao CT, Matsumura SY, Mejza SJ, Paborsky LR, Leung LLK; Conversion of thrombin into an anticoagulant by protein engineering; *Nature*; 378:413-16, 1995.
7. Tsiang M, Paborsky LR, Li W-X, Jain AK, Mao CT, Dunn KE, Lee DW, Matsumura SJ, Matteucci MD, **Coutré SE**, Leung LLK, Gibbs CS; Protein engineering thrombin for optimal specificity and potency of anticoagulant activity *in vivo*; *Biochemistry*; 35:16449-57, 1996.
8. He GX, Krawczyk SH, Swaminathan S, Shea RG, Dougherty JP, Terhorst T, Law VS, Griffin LC, **Coutré S**, Bischofberger N; N2- and C8-substituted oligodeoxynucleotides with enhanced thrombin inhibitory activity in vitro and in vivo; *J Med Chem*; 41(13):2234-42,1998.
9. He GX, Williams JP, Postich MJ, Swaminathan S, Shea RG, Terhorst T, Law VS, Mao CT, Sueoka C, **Coutré S**, Bischofberger N; In vitro and in vivo activities of oligodeoxynucleotide-based thrombin inhibitors containing neutral formacetal linkages; *J Med Chem*; 41(22):4224-31, 1998.
10. Appelbaum FR, Baer MR, Carabasi MH, **Coutré SE**, Erba HP, Estey E, Glenn MJ, Kraut EH, Maslak P, Millenson M, Miller CB, Saba HI, Stone R, Tallman MS. NCCN Practice Guidelines for Acute Myelogenous Leukemia. *Oncology (Huntingt)*; 14(11A):53-61, 2000.
11. Evans WE, Hon YY, Bomgaars L, **Coutré S**, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. *J Clin Oncol*; 19(8):2293-301, 2001.
12. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, **Coutré S**, Dahlberg S, Ellison R, Warrell RP Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. *J Clin Oncol*; 19(18):3852-60, 2001.*
13. Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, **Coutré SE**. Cytomegalovirus Viremia During Campath-1H Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia. *Clin Lymphoma*; 3:105-10, 2002.
14. Keating MJ, Cazin B, **Coutré S**, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjonnfjord G, Bekradda M, Itzhaki M, Herait. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. *J Clin Oncol*; 20(1):205-13, 2002.*
15. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, **Coutré** S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. *Blood*; 99(10):3530-9, 2002.*
16. Cao TM and **Coutré SE**. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H). *Hematology*; 8(1):1-6, 2003.
17. Cools J, DeAngelo D, Gotlib J, Stover EH, Legare RD, Malone J, Kutok J, Boulton CL, Williams I, Clark J, Galinksy I, Griffin JD, Cross NP, Tefferi A, Alam R, Cortes J, Kantarjian H, Schrier SL, Schmid J, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Marynen P, **Coutré SE**, Stone RD, and Gilliland DG. A novel tyrosine kinase created by fusion of the *PDGFRA* and *FIP1L1* genes represents the therapeutic target of imatinib in idiopathic hypereosinophilic syndromes. *New Engl J Med*; 348:1201-14, 2003.*
18. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, **Coutre SE**, Stone RM, DeAngelo DJ, Marynen P,

Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, and Gilliland DG. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. *Cancer Cell*; 3:459-69, 2003.

19. Cao TM and **Coutré SE.** Management of advanced chronic lymphocytic leukemia. *Current Hematology Reports*; 2:65-72,2003.
20. **Coutré S** and Gotlib J. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. *Seminars in Cancer Biology*; 14:23-31, 2004.
21. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, and **Coutre SE**. The FIP1L1-PDGFRa fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. *Blood*; 103:2879-91, 2004.
22. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, and **Coutre S**. Practical caveats to the classification of hypereosinophilic syndrome and chronic eosinophilic leukemia as mutually exclusive diagnoses. *Blood*; 104:3836-7, 2004.
23. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, **Coutre S**, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. *Blood*. 104:1534-41, 2004.*
24. Keating M, **Coutré S**, Rai K, Osterborg A, Faderl S, Kennedy B, Kipps T, Bodey G, Byrd JC, Rosen S, Dearden C, Dyer MJ, Hillmen P "Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia." *Clin Lymphoma*; 4:220-7, 2004.
25. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, **Coutre SE**. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. *Blood*; 106:2865-70, 2005.
26. Faderl S, **Coutre S**, Byrd JC, Dearden C, Denes A, Dyer MJ, Gregory SA, Gribben JG, Hillmen P, Keating M, Rosen S, Venugopal P, Rai K. The evolving role of alemtuzumab in management of patients with CLL. *Leukemia*; 19:2147-52, 2005.
27. Ma JF, **Coutre SE**, Curet MJ, Brooks JD. Refractory hematuria from amyloidosis successfully treated by splenectomy. *Urology*; 67:1085e13-15, 2006.
    Role: Hematologic consultant; reviewed manuscript draft.
28. O'Donnell MR, Appelbaum FR, Baer MR, Byrd JC, **Coutre SE**, Damon LE, Erba HP, Estey E, Foran J, Lancet J, Maness LJ, Maslak PG, Millenson M, Moore JO, Przepiorka D, Shami P, Smith BD, Stone RM, Tallman MS. Acute myeloid leukemia clinical practice guidelines in oncology. *J Natl Compr Canc Netw*; 4:16-36, 2006.
29. Nabhan C, **Coutre S**, Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? *Br J Haematol*; 136:379-92, 2007.
30. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, **Coutre S**, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. *Blood*, 109:3207-13, 2007.*
31. Deangelo DJ, Yu D, Johnson JL, **Coutre SE**, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801. *Blood*, 109:5136-42, 2007.
    Role: Southwest Oncology Group PI for this joint CALGB/SWOG national trial.
32. Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, **Coutre SE,** Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. International

Standardized Approach for Flow Cytometric Residual Disease Monitoring in Chronic Lymphocytic Leukemia. *Leukemia;* 21:956-64, 2007.

Role: Stanford clinician for this international collaborative effort involving clinicians and pathologists; reviewed manuscript draft.

33. Moayeri SE, **Coutre SE**, Ramirez EJ, Westphal LM. Von Willebrand's Disease Presenting as Recurrent Hemorrhage Following Transvaginal Oocyte Retrieval. *American J Obst Gyn;* 196:10-1,2007.

    Role: Hematologic consultant; reviewed manuscript draft.

34. Hamilton CA, Kao JM, **Coutre SE**, Teng NN. Acute Postoperative Thrombotic Thrombocytopenic Purpura Following Hysterectomy and Lymphadenectomy for Endometrial Cancer. *Gynecol Oncol*; 106:423-6, 2007.

    Role: Hematologic consultant; reviewed manuscript draft.

35. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, **Coutre S**. Dasatinib Induces Rapid Hematologic and Cytogenetic Responses in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia with Resistance or Intolerance to Imatinib: Interim Results of a Phase 2 Study. *Blood*; 110:2309-15, 2007.
36. Cortes J, Kim D-W, Raffoux E, Martinelli G, Ritchie E, Roy, L, **Coutre S,** Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brümmendorf TH, Michallat M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JMA, Talpaz M. Efficacy and Safety of Dasatinib in Imatinib-resistant or –intolerant patients with chronic myeloid leukemia in blast phase. *Leukemia*; 22:2176-83, 2008.*
37. **Coutré S**. Myelodysplastic syndromes: disease overview and therapy options. *Manag Care;* 17(7 Suppl 6):3-8, 2008.
38. O'Donnell MR, Appelbaum FR, **Coutre SE**, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, Maslak PG, Millenson M, Moore JO, Ravandi F, Schuening F, Shami P, Smith BD, Stone RM, Tallman MS, Wang E, White FL. Acute myeloid leukemia. *J Natl Compr Canc*; 6:962-93, 2008.
39. Kohrt HE, **Coutre SE**. Optimizing therapy for acute myeloid leukemia. *J Natl Compr Canc Netw*; 6:1003-16, 2008.
40. Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, Kumar S, Bahlis NJ, Alsina M, Vescio R, **Coutre SE**, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. *Br J Haematol;* 146:164-70, 2009.
41. Ho DY, Lin M, Schaenman J, Rosso F, Leung AN, **Coutre SE**, Sista RR, Montoya JG. Yield of diagnostic procedures for invasive fungal infections in neutropenic febrile patients with chest computed tomography abnormalities. Mycoses. Sep 28, 2009. [Epub ahead of print]

* My participation in clinical investigative trials has often been in the context of multi-institutional trials. In many of these trials I am not the primary or senior author of published manuscripts from these trials. In all cases, however, I was the principal investigator at Stanford and my contributions typically included participation in trial design, collection, analysis and interpretation of data, enrollment of all or the majority of patients at Stanford, participation in the review of the manuscript, and in some cases presentation of the work at national and international meetings. This applies to the following articles in my bibliography: 12, 14, 15, 17, 23, 30, 36, and 40.

Book Chapters

1. **Coutré S**, Foung SKH, Engleman EG; Human T-lymphocyte subsets and T-T hybridomas; in: Human hybridomas and monoclonal antibodies, Engleman EG, et al, eds, Plenum Press, New York; 311-21, 1985.
2. **Coutré S**, Leung L; Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa; in: Annual Review Medicine; 46:257-65, 1995.
3. **Coutré S**, Hirsch, J. Eds. Anticoagulant therapy; in: Best Practice in Medicine; 1998.
4. **Coutré S**, Heparin-induced thrombocytopenia; UpToDate, Hematology Section; Burton D. Rose, ed.
5. **Coutré S**, Pre-operative evaluation of bleeding risk; UpToDate, Hematology Section; Burton D. Rose, ed.
6. **Coutré S**, Congenital and acquired disorders of platelet function; UpToDate, Hematology Section; Burton D. Rose, ed.
7. **Coutré S**, Acquired inhibitors of coagulation; UpToDate, Hematology Section; Burton D. Rose, ed.
8. Cao TM and **Coutré SE**; Acute lymphocytic leukemia in adults; in: Wintrobe's Clinical Hematology, 11th Edition, Lippincott, Williams and Wilkins, Philadelphia, 2004.
9. Itakura H and **Coutré SE**; Acute lymphocytic leukemia in adults; in: Wintrobe's Clinical Hematology, 12th Edition, Lippincott, Williams and Wilkins, Philadelphia, 2009.

Abstracts

1. **Coutré S**, Rai KR, Keating MJU, Gribben JG, Flinn I, Rabinowe S, Rizzieri D. Efficacy and Safety of Alemtuzumab (Campth-1H) Used on a Compassionate Basis in Refractory T-PLL. *Blood*; 98:11, 366a, 2001.
2. Cao TM, Nguyen DD, Dugan K, Starcher SA, Fechter L, **Coutré SE**. Incidence of Cytomegalovirus (CMV) Viremia during Campath-1H Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Prolymphocytic Leukemia (PLL). *Blood*; 98:11, 366a, 2001.
3. Gotlib J, Jones CD, Zheng K, Yeung C, Dugan K, Fechter L, Falkow R, Zehnder JL, **Coutré S**. Real-Time PCR Assay For Quantitation of BCR-ABL mRNA in patients with chronic phase CML treated with the tyrosine kinase inhibitor Gleevec™ (STI-571). *Blood*; 98:11, 258b-259b, 2001.
4. Gotlib J, Malone JM, DeAngelo DJ, Stone RM, Gilliand DG, Clark J, Tefferi A, Alam R, Schrier SL, **Coutré SE**. Imatinib Mesylate (GLEEVEC) Induces Rapid and Complete Hematologic Remissions in Patients with Idiopathic Hypereosinophilic Syndrome (HES) without Evidence of BCR-ABL or Activating Mutations in c-KIT and Platelet-Derived Growth Factor Receptor-Beta (PDGFR-a). *Blood*; 100:11, 798a, 2002.
5. Gotlib J, Cao T, Jones C, Yeung C, Dugan K, Falkow R, Zehnder JL, **Coutré SE**. Serial real-time quantatative PCR monitoring reveals frequent and rapid relapses after molecular remissions in chronic phase (CP) CML patients treated with imatinib mesylate (Gleevec™). *Blood*; 100:11, 547a, 2002.
6. Gotlib J, Berube C, Ruan J, Growney J, Dugan K, Falkow R, Rosamilia M, Resta D, Cohen P, Fabbro D, Heinrich M, Gilliland DG, **Coutre S**. PKC412, Inhibitor of the KIT Tyrosine Kinase, Demonstrates Efficacy in Mast Cell Leukemia with the D816V KIT Mutation. *Blood;* 102:11, 2003.
7. Jamieson C, Gotlib J, **Coutre S**, Li K, Weissman I. Predictive Progenitor Profiling in Chronic Myelomonocytic Leukemia. *Blood;* 104:11, 2004.
8. Rawstron AC, Villamor N, Zehnder JL, Ghia P, Ritgen M, Bottcher S, Lozanski G, Mone AP, Colomer D, Moreno C, Geuna M, Evans PA, Kneba M, Natkunam Y, **Coutre SE**, Caligaris-Cappio F, Hallek MJ, Byrd JC, Montserrat E, Hillmen P. International Standardized

Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL. CLL MRD Group, International Collaboration. *Blood;* 104:11, 2004.

9. Jamieson C, Gotlib J, Chao M, Mariappan MR, LayRaj M, Jones C, Zehnder J, Durocher J, Lilleberg S, **Coutre S**, Weissman I. Molecular progenitor profiling in human myeloproliferative disorders. *Blood*; 106:11, 2005.
10. Levis M, Smith BD, Beran M, Baer MR, Erba HP, Cripe L, **Coutre S**, Advani A, Perl A, Devetten M, Stuart R, Tallman MS, Brown P, Tremmel L, Small D. A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition. *Blood*; 106:11, 2005.
11. Talpaz M, Rousselot P, Kim DW, Guilhot F, Corm S, Bleickardt E, Zink R, Rosti G, **Coutre S**, Sawyers C. A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 'START-B' Study. *Blood*; 106:11, 2005.
12. Weiss MA, Heffner L, Lamanna N, Kalaycio M, Schiller G, **Coutre S**, Maslak P, Jurcic J, Panageas K, Scheinberg DA, for the ALL-4 Consortium. A randomized trial demonstrating the superiority of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL. *ASCO Annual Meeting Proceedings*; 23:16S, 2005.
13. **Coutre S,** Dasatinib (D) in Patients(pts) with Chronic Myelogenous Leukemia (CML) in Lymphoid Blast Crisis (LB-CML) or Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) who are Imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L" Study. *ASCO Annual Meeting Proceedings*; 23:16S, 2006.
14. Martinelli G, Hochhaus A, **Coutre S**, Apperley JF, Shah N, Gollerkeri A, Agarwal P, Ottmann OG. Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid Blast (CML-LB) or Myeloid Blast (CML-MB) Phase who are Imatinib-resistant (Im-r) or -intolerant (Im-i). *ASH Annual Meeting* Abstracts; 108: 745, 2006.
15. Dombret H, Ottmann O, Rosti G, Simonsson B, Larson R, Gollerkeri A, Apanovitch A, Radich J, **Coutre S**. Dasatinib (SPRYCEL®) in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia who are Imatinib- Resistant (im-r) or -Intolerant (im-i): Updated results from the CA180-015 'START-L' study. *ASH Annual Meeting* Abstracts; 24:6528, 2006.
16. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, **Coutre S**, Feusner JH, Gregory J,Coulban S, Appelbaum FR, Tallman MS, and Larson RA. Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710. *ASH Annual Meeting* Abstracts; 108: 745, 2006.
17. Brodsky RA, Muus P, Dührsen U, Hill A, Bessler M, **Coutre S**, De Paz R, MD7*, Moskovits T, Nakamura R, Van den Neste E, Zanella A, Quinn-Senger K, Kroon H-A, Cella D. Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III TRIUMPH Study Results. *ASH Annual Meeting* Abstracts; 108: 3770, 2006.
18. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, **Coutre S**, Feusner JH, Appelbaum FR, Tallman MS, and Larson RA. Consolidation with arsenic trioxide (As2O3) significantly improves event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. *ASCO Annual Meeting Proceedings* 2007.
19. Klisovic R, Tricot G, **Coutre S**, Kovacsovics T, Giles F, Genn T, Bol D, Strovel J, Hamilton M, and Mitchell B. A Phase I trial of AVN944 in patients with advanced hematologic malignancies. *ASCO Annual Meeting Proceedings*; 25:14026, 2007.
20. Muus P, Ulrich Dührsen U, Elebute M, Browne P, Urbano-Ispizua A, **Coutre S**, Van den Neste E, De Paz R, Konkle B, Moskovits T, Nakamura R, Zanella A, Hillmen P, Rother R, and Socié G. The clinical benefit of eculizumab is demonstrable in all subpopulations of

patients with paroxysmal nocturnal hemoglobinuria (pnh) with hemolysis. *ASCO Annual Meeting Proceedings* 2007.

21. Klisovic RB, **Coutre S**, Kovacsovics TJ, Kantarjiam HM, Tricot GJ, Strovel JW, Genna T, Bol DK, Hamilton M, and Mitchell BS. Clinical-biomarker correlations in adult AML patients in a phase I trial of AVN944 support observations of clinical effect and provide hypotheses for patient selection criteria for further clinical trials. *ASH Annual Meeting* Abstracts; 110: 273a, 2007.
22. Liedtke M, Twist C, Bieber M, Bhat N, Teng N, and **Coutre S**. A phase I study of a novel human monoclonal antibody (mAB216) with chemotherapy for the treatment of patients with relapsed or refractory B-lineage acute lymphoblastic leukemia. *ASH Annual Meeting* Abstracts; 110: 833a, 2007.
23. Fan AC, Orban MW, Lee HE, Shirer AE, Rajwanshi, Kong RC, Natkunam Y, **Coutre S**, and Felsher DW. Biological and clinical effects of single agent treatment with atorvastatin in patients with non-Hodgkin's lymphoma. *ASCO Meeting Proceedings*; 26: 8529, 2008.
24. Medeiros BC, Gotlib JR, **Coutre SE**, Mignea A, and Zehnder J. Tailored temozolomide therapy for elderly patients with acute myeloid leukemia. *ASH Annual Meeting* Abstracts; 112: 954a, 2008.
25. Wierda WG, Chen R, Plunkett W, **Coutre S**, Badros AZ, Popplewell L, Siegel D, Sinha R, Harvey D, Fox J, Mahadocon K, Kegley P, and Bolton MG. A phase 1 trial of SNS-032, a potent and specific CDK 2, 7 and 9 inhibitor, in chronic lymphocytic leukemia and multiple myeloma. *ASH Annual Meeting* Abstracts; 112: 3178a, 2008.
26. Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, **Coutre S**, Stock W, Borthakur G, Chiao J, and Kantarjian H. A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. *ASCO Annual Meeting Proceedings*; 27: 7021, 2009.
27. Medeiros BC, Gotlib JR, **Coutre SE**, Jones C, Khan SA, Rajwanshi R, and Zehnder J. Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. *ASCO Meeting Proceedings*; 27: 7052, 2009.
28. Fan AC, Orban MW, Shirer AE, Rajwanshi R, Kong C, Natkunam Y, Lee HE, **Coutre S**, and Felsher DW. Nanoscale analysis of changes in signaling proteins in patients treated with single agent atorvastatin for low-grade or refractory NHL. *ASCO Meeting Proceedings*; 27: 11011, 2009.
29. Advani A, Holly Gundacker H, Sala-Torra O, Radich J, Lai R, Slovak ML, Lancet JE, **Coutre S**, Stuart RK, Mims MP, Stiff P, and Appelbaum FR. Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia. *ASH Annual Meeting* Abstracts 114: 3094, 2009.
30. Alizadeh AA, McClellan JS, Gotlib JR, **Coutre S**, Majeti R, Kohrt HE, and Medeiros BC. Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. *ASH Annual Meeting* Abstracts 114: 1015, 2009.
31. Cortes-Franco J, **Coutre S**, Di Bona E, Lo-Coco F, Wetzler M, Sanz M, Wieland S, Barber JR, and Kantarjian HM. A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia (APL) Patients (PTS) Who Have Received Prior Therapy with All-Trans Retinoic Acid and Arsenic Trioxide (STAR-1 trial). *ASH Annual Meeting* Abstracts 114: 2050, 2009.
32. Edward DB, Medeiros BC, Balaian L, Roque T, Corringham S, Rajwanshi R, **Coutre S**, Gotlib JR, Bashey A, and Messer K. A Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies. *ASH Annual Meeting* Abstracts 114: 2049, 2009.
42. Flinn IW, Byrd JC, Furman RR, Brown JR, Benson DM, **Coutre SE**, Kahl BD, Smith BD, Wagner-Johnston ND, Spurgeon SE, Giese NA, and Albert Yu. Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110{Delta} Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies. *ASH Annual Meeting* Abstracts 114: 922, 2009.

43. Kantarjian HM, Garcia-Manero G, Luger S, Venugopal P, Maness LJ, Wetzler M, Stock W, **Coutre S**, Borthakur G, and Chiao J. A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse. *ASH Annual Meeting* Abstracts 114: 1061, 2009.
44. Kohrt HE, Patel S, Ho M, Owen T, Majeti R, Gotlib JR, **Coutre S**, Medeiros BC, and Alizadeh AA. Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). *ASH Annual Meeting* Abstracts 114: 1617, 2009.
45. Kreitman RJ, Tallman MS, **Coutre S**, Robak T, Wilson WH, Stetler-Stevenson M, Noel P, FitzGerald DJ, Buzoianu M, Lechleider R, Kaucic K, and Pastan I. Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia. *ASH Annual Meeting* Abstracts 114: 888, 2009.
46. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, **Coutre S**, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Jedrzejczak WW, Juliusson G, Litzow MR, Petersdorf S, Miguel Sanz*,Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, and Smith BD. Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse. *ASH Annual Meeting* Abstracts 114: 788, 2009.
47. O'Brien S, Schiller G, Damon LE, Lister J, Ravandi F, Douer D, Masood A, Ben-Yehuda D, Rowe JM, Gökbuget N, Aulitzky W, Stock W, **Coutre S**, Heffner L, Larson ML, Seiter K, Hagey AE, Deitcher SR, and Kantarjian HM. Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo(R)) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines. *ASH Annual Meeting* Abstracts 114: 3088, 2009.

Invited Presentations (selected)

1997 “Novel Approaches for the Prophylaxis and Treatment of Venous Thromboembolism”. Department of Medicine, University of Louisville, Grand Rounds; Louisville, KY, November.

1999 “New Antithrombotic Therapies”. Department of Medicine, Stanford University Medical School, Grand Rounds, Stanford, CA, March.

2001 “Therapy for Acute Promyelocytic Leukemia”. Advances in the Treatment of Adult Acute Leukemia Conference; City of Hope National Medical Center, Newport Beach, CA, March.

2002 “Current Advances in the Treatment of Chronic Lymphocytic Leukemia”. Cleveland Clinic Cancer Center, Cleveland, OH, June.

2002 “107 Years of Antibody Therapy for Malignancy: Current Directions in the Treatment of Lymphoma and Leukemia”. American Society of Hematology pre-symposia, Philadelphia, PA, December.

2003 “Hitting the Target: New Approaches in Cancer Therapy”. American Society of Clinical Oncology pre-symposia, Chicago, IL, May.

2003 “Risks and Benefits of Moving Towards a Cure in the Treatment of CLL”, Chair, American Society of Hematology pre-symposia, San Diego, CA, December.

2004 “ASCO/American Society of Hematology Symposium: New Issues in Hemostasis and Thrombosis for Practicing Oncologists”. American Society of Clinical Oncology, New Orleans, LA, June.

2004 “Improving Survival in CLL: Clinical Implications of Molecular Remission”. American Society of Hematology pre-symposium, San Diego, CA, December.

2006 “Emerging Trends in the Treatment of Multiple Myeloma”. BMT Tandem Meetings pre-symposium, Honolulu, HI, February.

2006 “Developments in the Treatment of Lymphoproliferative Disorders; Rising to the New Challenges of CLL Therapy, American Society of Hematology pre-symposium, Orlando, FL, December.

2007 “Consolidation with Arsenic Trioxide Significantly Improves Event-Free Survival and Overall Survival Among Patients with Newly Diagnosed Acute Promyelocytic Leukemia: North American Intergroup Protocol C9710”. Southwest Oncology Group Spring Meeting, Chicago, IL, May.

2008 “How I Treat Acute Promyelocytic Leukemia”. City of Hope National Medical Center, “How the Experts Treat Hematologic Malignancies” Conference, Kauai, HI, January.

2008 “Acute Leukemias and Myelodysplastic Syndromes”, Hoag Cancer Center Cancer Treatment Update, Newport Beach, CA, February.

2009 “How I Treat Chronic Lymphocytic Leukemia”. City of Hope National Medical Center, “How the Experts Treat Hematologic Malignancies” Conference, Kauai, HI, January.

2009 “Risk Stratification and the Management of Acute Promyelocytic Leukemia”, “NCCN 4th Annual Congress: Hematologic Malignancies”, New York, NY, September.